



国内版 国际版

The optimized timing of using infliximab in perianal fistulizing



Chat with Bing

Sign in

Add Bing Firefox extension

ALL IMAGES VIDEOS

开启取词

26,600 Results Any time

Fistulizing Crohn's disease: Diagnosis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040755>

Jan 08, 2013 · Management of perianal fistulizing Crohn's disease. The main goals of treatment in perianal fistulizing Crohn's disease are abscess drainage prior to initiating immunosuppressive therapy, resolution of fistula discharge, preservation of continence and avoidance of ...

Cited by: 23 Author: Krisztina Gecse, Reena Khanna, Jaap St...

Publish Year: 2013

Magnetic resonance imaging of the effects of infliximab on ...

<https://www.sciencedirect.com/science/article/pii/S0002927002059099>

Although the clinical efficacy of infliximab as measured by closure of fistulas in Crohn's disease has been demonstrated, its influence on the inflammatory changes in the fistula tracks is less clear. The aim of the present study was to assess the behavior of perianal fistulas before and after infliximab ...

Cited by: 430 Author: Gert Van Assche, Dirk Vanbeckevoort, Di...

Publish Year: 2003

Treatment of Perianal Fistulizing Crohn's Disease with ...

<https://academic.oup.com/ibdjournal/article/9/2/98/4718302>

Mar 01, 2003 · Prior to infliximab or EUA, the 16 male and 16 female patients had actively draining perianal fistulas for time periods ranging from 2 weeks to 1 year (mean duration 4 months), and Crohn's disease for 1 to 37 years (mean duration 11 years).

Cited by: 304 Author: Miguel Regueiro, Houssam Mardini

Publish Year: 2003

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

<https://www.nejm.org/doi/full/10.1056/NEJMoa030815>

Patients with fistulizing Crohn's disease who have a response to induction therapy with infliximab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.

Cited by: 2218 Author: Bruce E. Sands, Frank H. Anderson, Cha...

Publish Year: 2004

Infliximab in the treatment of Crohn's disease

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936311>



Get quick access to Bing with the Bing extension for Firefox

MAYBE LATER

YES



53067-Review-check.docx

 Quotes Excluded
 Bibliography Excluded

 2%
 SIMILAR

 Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 53067

Manuscript Type: OPINION REVIEW

Optimized timing of using infliximab in perianal fistulizing Crohn's disease

 Sun XL *et al.* Infliximab in perianal fistulizing Crohn's disease

Xue-Liang Sun, Shi-Yi Chen, Shan-Shan Tao, Li-Chao Qiao, Hong-Jin Chen, Bo-Lin Yang

Abstract

Infliximab (IFX), as a first-line therapy, can alter the natural progression of Crohn's disease (CD), promote mucosal healing and decrease complications, hospitalizations, and the incidence of surgery. Perianal fistulas are responsible for the refractoriness of CD and indicate a more aggressive disease. IFX has been demonstrated as the most effective drug for the treatment of perianal fistulizing CD. Unfortunately, a significant proportion of patients only partially

Match Overview

1	Internet 19 words crawled on 25-Mar-2017 www.e-sciencecentral.org	1%
2	Crossref 15 words Mohammed Razvi, Mark Lazarev. "Optimization of biologic... herapy in Crohn's disease", <i>Expert Opinion on Biological Th</i>	<1%
3	Crossref 14 words Nikolas Plevris, Philip W. Jenkinson, Ian D. Arnott, Gareth R. Jones, Charlie W. Lees. "Higher anti-tumor necrosis facto	<1%
4	Internet 12 words crawled on 31-Jan-2020 f6publishing.blob.core.windows.net	<1%



ALL

IMAGES

VIDEOS

27,300 Results

Any time ▾

Evaluating the effectiveness of infliximab on perianal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375345>

Perianal fistulizing Crohn's disease (PFCD) has a serious **impact** on quality of life and **mental** health . It is always indicative of a more aggressive and refractory **disease** phenotype .

Cited by: 1

Author: Xiaohan Yan, Mingming Zhu, Qi Feng, Yunq...

Publish Year: 2019

Treatment of complex perianal fistulas in Crohn disease ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947112>

Perianal fistulas affect up to 20%–30% of patients with **Crohn disease**. , The treatment of **anorectal fistula associated with Crohn disease** is difficult, particularly when the rectum is diseased, and optimal management is still a matter of debate.

Cited by: 82

Author: Guido Sciaudone, Crescenzo Di Stazio, Pao...

Publish Year: 2010

Treatment of Perianal Fistulizing Crohn's Disease with ...

<https://academic.oup.com/ibdjournal/article/9/2/98/4718302> ▾

Infliximab

Common brand names: Inflectra, Remicade

This medication is used to treat certain types of arthritis, certain bowel diseases, and a certain severe skin disease.

Precautions



Side Effects



Interactions



Warnings

Brand names: [Remicade](#) · [Inflectra](#) · [Renflexis](#)

Drug classes: Tumor Necrosis Factor Blocker · Gastrointestinal Agent

Pregnancy category: Consult a doctor



Optimized timing of using infliximab in perianal fistulizing Crohn's disease



YJ



ALL

IMAGES

VIDEOS

27,400 Results

Any time

Evaluating the effectiveness of infliximab on perianal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375345>

Introduction. **Perianal fistulizing Crohn's disease** (PFCD) has a serious impact on quality of life and mental health [].It is always indicative of a more aggressive and refractory **disease** phenotype [].A population-based study found that the incidence of **perianal** fistula in patients with **Crohn's disease** (CD) is 21–23% and that the cumulative incidences of the condition at 1, 5, 10 and 20 ...

Cited by: 1

Author: Xiaohan Yan, Mingming Zhu, Qi Feng, Yu...

Publish Year: 2019

Treatment of Perianal Fistulizing Crohn's Disease with ...

<https://academic.oup.com/ibdjournal/article/9/2/98/4718302>

Mar 01, 2003 · Prior to infliximab or EUA, the 16 male and 16 female patients had actively draining perianal fistulas for time periods ranging from **2 weeks to 1 year** (mean duration **4 months**), and **Crohn's disease for 1 to 37 years** (mean duration 11 years).

Cited by: 305

Author: Miguel Regueiro, Houssam Mardini

Publish Year: 2003

Treatment of perianal fistulizing Crohn's disease ...

<https://onlinelibrary.wiley.com/doi/10.1111/i.1365-2036.2004.02060.x/references>

Infliximab

Common brand names: Inflectra, Remicade

This medication is used to treat certain types of arthritis, certain bowel diseases, and a certain severe skin disease.

Precautions



Side Effects



Interactions



Warnings

Brand names: Remicade · Inflectra · Renflexis

Drug classes: Tumor Necrosis Factor Blocker · Gastrointestinal Agent

Pregnancy category: Consult a doctor

Availability: Prescription needed